This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.
In your application messsage, please share your background and what you can contribute to the group.
Company Overview and News
Huntington Ingalls Industries’ (NYSE:HII) Ingalls Shipbuilding division successfully launched the Arleigh Burke-class (DDG 51) guided missile destroyer Frank E. Petersen Jr. (DDG 121) on Friday.
The first ship in the nation’s newest class of nuclear-powered aircraft carriers, USS Gerald R. Ford (CVN 78), returned to Huntington Ingalls Industries’ (NYSE:HII) Newport News Shipbuilding division Sunday for its scheduled post-shakedown availability and selected restricted availability.
The U.S. Navy’s newest aircraft carrier, USS Gerald R. Ford (CVN-78) started a year-long post-shakedown availability/selected restricted availability (PSA/SRA) upgrade and maintenance period on Saturday.CVN-78 first arrived at Huntington Ingalls Industries’…
PASCAGOULA, Miss., July 16, 2018 (GLOBE NEWSWIRE) -- Huntington Ingalls Industries’ (NYSE:HII) Ingalls Shipbuilding division successfully launched the Arleigh Burke-class (DDG 51) guided missile destroyer Frank E. Petersen Jr. (DDG 121) on Friday.
NEWPORT NEWS, Va., July 10, 2018 (GLOBE NEWSWIRE) -- Huntington Ingalls Industries (NYSE:HII) announced today that the U.S. Department of Energy’s (DOE) National Nuclear Security Administration (NNSA) has issued a notice to proceed into transition for the management transition process at Los Alamos National Laboratory (LANL) in Los Alamos, New Mexico, to Triad National Security LLC. After a four-month transition period, the team will assume full management and operational responsibility for the laboratory.
Huntington Ingalls Industries, Inc.'s (HII - Free Report) Ingalls Shipbuilding business unit recently secured a modification contract for carrying out emergent repair and restoration of USS Fitzgerald (DDG 62). The contract was awarded by the Naval Sea Systems Command, Washington, DC. The deal, valued at $27.5 million, also entails for the additional collision repairs along with the maintenance and modernization of the USS Fitzgerald.
NOC WAIR HII TXT
NEWPORT NEWS, Va., July 05, 2018 (GLOBE NEWSWIRE) -- Huntington Ingalls Industries (NYSE:HII) will release its second quarter 2018 financial results on Thursday, Aug. 2 and host an earnings conference call at 9 a.m. EDT the same day. The call will be webcast live on HII’s website: http://www.huntingtoningalls.com.
NEWPORT NEWS, Va., July 03, 2018 (GLOBE NEWSWIRE) -- Huntington Ingalls Industries (NYSE:HII) announced today that Bryan Caccavale has been promoted to vice president of strategic sourcing for the company’s Newport News Shipbuilding division. He assumed his new role this week and reports to the shipyard’s president, Jennifer Boykin.
On Jun 22, the European Union (EU) slapped tariffs on $3.2 billion of American products in response to taxes imposed on steel and aluminum by the United States. It seems like trade tensions have rapidly spread to other parts of the world in a ripple effect of the ongoing dispute between America and China over tariff impositions and trade protectionism issues.
LMT GD NOC HII BOE BA PII
Huntington Ingalls Industries, Inc.’s (HII - Free Report) business segment, Newport News, recently secured a modification contract to purchase additional long lead time material for supporting the USS Enterprise (CVN 80). Work related to the deal is scheduled to be over by February 2027.
NOC WAIR HII GM.WS.A GM.WS.B GM.WS.C GM TXT GM.WSB PII
The US Navy (USN) awarded Huntington Ingalls Industries (HII) Newport News Shipbuilding unit a USD200.4 million undefinitised fixed-price, incentive firm target modification on 28 June for the purchase of additional long-lead time material for Ford-class aircraft carrier Enterprise (CVN 80).
NEWPORT NEWS, Va., June 28, 2018 (GLOBE NEWSWIRE) -- Huntington Ingalls Industries (NYSE:HII) announced today that the HII Scholarship Fund, now in its third year, has awarded 100 pre-kindergarten and post-secondary scholarships for the 2018-2019 school year. To date, nearly 400 scholarships have been awarded or renewed for a total of more than $1 million, providing educational opportunities to 271 children of employees across the HII enterprise.
NEWPORT NEWS, Va., June 26, 2018 (GLOBE NEWSWIRE) -- Huntington Ingalls Industries (HII) (NYSE:HII) has appointed Sharon Brady chief operating officer of SN3, part of Huntington Ingalls Industries’ Technical Solutions division, effective June 4.
Huntington Ingalls Industries’ (NYSE:HII) Newport News Shipbuilding division today delivered the newest nuclear-powered fast attack submarine to the U.S. Navy.
NEWPORT NEWS, Va., June 25, 2018 (GLOBE NEWSWIRE) -- Huntington Ingalls Industries’ (NYSE:HII) Newport News Shipbuilding division today delivered the newest nuclear-powered fast attack submarine to the U.S. Navy.
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
Silicon Investor Message Boards
This table lists all message boards related to HII / Huntington Ingalls Industries, Inc. on message board site Silicon Investor.
|T-3 Energy (formerly IHII)||Highland Holdings Intu0027l - HHII|
as of ET